BioInformant

Your Global Leader in Stem Cell Market Research

Home » Pluristem Therapeutics » Page 2

Pluristem Enters into Licensing Agreement with TES Holdings to Acquire Rights for Placental Cell Therapy Patent

By Leave a Comment

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.  Pluristem’s core technology is placenta-derived cells that are being developed as a real ‘off-the-shelf’ therapeutic product for critical high unmet need indications, where there are limited or no alternative treatment options available. For example, Pluristem’s lead product, PLX PAD is in clinical development for diseases such as critical limb ischemia (CLI) and hip fractures.

In major news released today, Pluristem announced that it entered into a licensing agreement with TES Holdings Co., Ltd. to obtain a key patent in Japan that will cover the treatment of ischemic diseases with placental cell therapy. This is a significant announcement, as the company released news last week that it had been granted two key cell therapy patents in Japan.

To learn more, see the full press release issued by Pluristem below or read our recent interview with Dr. Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics.

Pluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke

Press Release; Haifa, Israel, April 21, 2016 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company’s IP coverage. This license follows Pluristem’s recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods. [Read more…]

Pluristem Fortifies IP Position and Partnering Potential in Japan with Two Key Cell Therapy Patents

By Leave a Comment

In major news released today, Pluristem Therapeutics announced that it had been granted two key cell therapy patents in Japan. Pluristem Therapeutics is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

Therefore, the patents pertain to the three-dimensional growth of placental and fat cells and the use of placental cells grown with 3D technology:

  1. Patent No. 5733894, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy
  2. Patent No. 5766041, titled “Pharmaceutical Composition for Enhancing Subject Hematopoietic System”

To learn more about the company, see our recent interview Dr. Racheli Ofir, VP Research & Intellectual Property for Pluristem Therapeutics. Or, read the full press release below, printed with permission from Dr. Ofir. [Read more…]

Did You See This Week’s Top Stem Cell News?

By Leave a Comment

We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!

Q&A Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]

Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

By 1 Comment

Pluristem TherapeuticsI had the honor of interviewing Dr. Racheli Ofir, Vice President (VP) of Research & Intellectual Property at Pluristem Therapeutics. Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

The company is at the forefront of placental-based cell therapy applications. In addition to other accomplishments, the company is now preparing for a proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI).

Interview with Dr. Racheli Ofir, VP of Research & IP at Pluristem Therapeutics

Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics
Dr. Racheli Ofir

Cade Hildreth: What is your background and how did you get involved with Pluristem?

Dr. Racheli Ofir:  I did my PhD and post-doc in cellular and developmental biology at the Technion in Haifa. I joined Pluristem 9 years ago and am responsible for the research activity of the company including efficacy and safety studies of Pluristem placenta-derived cells, as well as revealing the underlying mechanism of action of the cells. [Read more…]

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

By Leave a Comment

Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).

To learn  more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]

BioInformant's World-Class Clients